10:11 AM EDT, 09/08/2025 (MT Newswires) -- Tevogen Bio ( TVGN ) said Monday it estimates a risk-adjusted net present value of $9 billion to $11 billion for TVGN-489, which is being developed as a potential treatment of COVID-19 in high-risk vulnerable patients and Long COVID.

The company said TVGN-489 is an allogeneic precision T cell therapy and the first clinical-stage product from its ExacTcell platform.

In a phase 1 proof-of-concept study, TVGN-489 was well-tolerated and there were no observed disease progression, recurrent COVID-19, or Long COVID cases in the treatment arm during six months of follow-up, Tevogen said.

The company's shares were up more than 3% in recent trading Monday.

Price: 0.89, Change: +0.03, Percent Change: +3.29